WEDNESDAY, Could 6, 2020 (HealthDay Information) — An experimental coronavirus vaccine commenced human trials in the United States on Monday, Pfizer and the German pharmaceutical firm BioNTech claimed.
If the trials show that the vaccine is helpful, it could be readily available for emergency use in the United States as early as September, The New York Instances reported.
The experimental vaccine, identified as BNT162, is currently being jointly designed by the two firms and the first human trials of the vaccine commenced in Germany previous thirty day period.
In the United States, the prepare is to examination the vaccine on 360 balanced volunteers in the first stage of the review, with up to eight,000 extra individuals added by the close of the 2nd stage, The Instances reported.
Other firms have also launched human trials of experimental coronavirus vaccines, but no vaccine has but been permitted to fight the virus.
Copyright © 2019 HealthDay. All legal rights reserved.